For most primary antibodies analyzed, sCRC with liver metastases and non-metastatic tumors had similar expression profiles, including similar (p > 0.05) levels of expression of MSH2, MSH6, c-Myc, Her2, p53, β-catenin, and Ki-67 antibodies (Table 1). Here, MSH6 is linked to metastatic neoplasm.